Results 211 to 220 of about 2,211,934 (230)

Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients

Neuroendocrinology, 2021
Introduction: Carcinoid syndrome is the most frequent functional syndrome of neuroendocrine neoplasia. It is characterized by flushing, diarrhea, wheezing, hypotension, and exanthema and may cause carcinoid heart disease.
Robert Fijałkowski, D. Reher, A. Rinke, T. Gress, J. Schrader, R. Baum, D. Kaemmerer, D. Hörsch   +7 more
semanticscholar   +1 more source

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Journal of Clinical Oncology, 2017
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome.
M. Kulke, D. Hörsch, M. Caplin, L. Anthony, E. Bergsland, K. Öberg, S. Welin, R. Warner, C. Lombard-Bohas, P. Kunz, E. Grande, J. Valle, D. Fleming, P. Lapuerta, Phillip L. Banks, S. Jackson, B. Zambrowicz, A. Sands, M. Pavel   +18 more
semanticscholar   +1 more source

Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review

Oncology, 2019
Background: Carcinoid syndrome symptoms significantly reduce quality of life in patients with neuroendocrine tumors. Evidence supporting the use of somatostatin analogues in carcinoid syndrome symptom control dates back 30 years.
E. Wolin, Al B Benson Iii
semanticscholar   +1 more source

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Endocrine Practice, 2016
OBJECTIVE To evaluate the efficacy and safety of lanreotide depot/autogel 120 mg for the control of carcinoid syndrome (CS) symptoms in patients with neuroendocrine tumors (NETs).
A. Vinik, E. Wolin, N. Liyanage, E. Gomez-Panzani, G. Fisher   +4 more
semanticscholar   +1 more source

Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome

, 2015
Excessive serotonin secretion is the hallmark of carcinoid syndrome. It leads to diarrhea, cramping, abdominal pain, wheezing and flushing. It is also associated with serious cardiac valve disease and lower life expectancy.
P. Lapuerta, B. Zambrowicz, D. Fleming, D. Wheeler, A. Sands   +4 more
semanticscholar   +1 more source

ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs).

, 2014
268 Background: Somatostatin analogs (SSAs) are the mainstay treatment for carcinoid syndrome. LAN is a long-acting SSA approved for this indication in >50 countries, but not yet in the US.
A. Vinik, E. Wolin, H. Audry, E. Gomez-Panzani   +3 more
semanticscholar   +1 more source